Provided by Tiger Fintech (Singapore) Pte. Ltd.

Innate Pharma SA

2.04
+0.04502.26%
Volume:18.67K
Turnover:37.36K
Market Cap:170.98M
PE:-4.51
High:2.05
Open:1.99
Low:1.96
Close:2.00
Loading ...

Press Release: Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results

Dow Jones
·
20 Mar

Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference

Business Wire
·
27 Feb

Innate Pharma Shares Rise After Breakthrough Therapy Designation for Lacutamab

Dow Jones
·
18 Feb

US Equity Futures Rise Pre-Bell as Wall Street Kicks Off Holiday-Shortened Trading Week

MT Newswires Live
·
18 Feb

Top Premarket Gainers

MT Newswires Live
·
18 Feb

Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome

Business Wire
·
17 Feb

Innate Pharma SA (IPHYF) Gets a Hold from Kepler Capital

TIPRANKS
·
14 Feb

3 Promising Penny Stocks With Market Caps Under US$500M

Simply Wall St.
·
01 Feb

Sector Update: Health Care Stocks Mixed Premarket Monday

MT Newswires Live
·
27 Jan

Innate Pharma doses first patient in IPH4502 study

TIPRANKS
·
27 Jan

Innate Pharma Doses First Patient in Phase 1 Trial of Cancer Drug Candidate

MT Newswires Live
·
27 Jan

Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors

Business Wire
·
27 Jan

Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York

Business Wire
·
21 Jan

Citi Keeps Their Buy Rating on Innate Pharma (IPHA)

TIPRANKS
·
20 Jan

Innate Pharma Price Target Maintained With a $11.50/Share by HC Wainwright & Co.

Dow Jones
·
17 Jan

Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024

Business Wire
·
16 Jan